BEAM

SEC source: 0000950170-23-027045 · ownership.xml · derivative · entry 1

Fishman Mark · CIK 0001786003 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,532

Underlying: Common Stock · 16,532 shares

Expires 2033-06-06

F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.

SEC source: 0000950170-23-027040 · ownership.xml · derivative · entry 1

Ho Carole · CIK 0001724605 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,532

Underlying: Common Stock · 16,532 shares

Expires 2033-06-06

F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.

SEC source: 0000899243-23-010819 · doc4.xml · nonDerivative · entry 2

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,117,979

F1 · kind: These shares of common stock were sold pursuant to a a Rule 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $28.81 to $29.10, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000899243-23-010818 · doc4.xml · nonDerivative · entry 2

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 112,290

F1 · kind: These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $28.79 to $29.10, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000899243-23-010817 · doc4.xml · nonDerivative · entry 2

Bellon Christine · CIK 0001963878 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 82,790

F1 · kind: These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $28.79 to $29.10, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000899243-23-010816 · doc4.xml · nonDerivative · entry 3

Simon Amy · CIK 0001963879 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 69,308

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $28.77 to $29.10, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000899243-23-010816 · doc4.xml · nonDerivative · entry 2

Simon Amy · CIK 0001963879 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 70,469

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $29.505 to $30.28, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000899243-23-010815 · doc4.xml · nonDerivative · entry 2

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,117

F1 · kind: These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $28.79 to $29.10, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000899243-23-010819 · doc4.xml · nonDerivative · entry 1

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,124,472

F1 · kind: These shares of common stock were sold pursuant to a a Rule 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023.

F2 · balance_after: Includes 480 shares acquired by the Reporting Person under the Beam Therapeutics Inc. Amended and Restated 2019 Employee Stock Purchase Plan on March 31, 2023.

SEC source: 0000899243-23-010818 · doc4.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 114,044

F1 · kind: These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023.

SEC source: 0000899243-23-010817 · doc4.xml · nonDerivative · entry 1

Bellon Christine · CIK 0001963878 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 83,951

F1 · kind: These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023.

SEC source: 0000899243-23-010816 · doc4.xml · nonDerivative · entry 1

Simon Amy · CIK 0001963879 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 80,962

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023.

F2 · balance_after: Includes 278 shares acquired by the Reporting Person under the Beam Therapeutics Inc. Amended and Restated 2019 Employee Stock Purchase Plan on March 31, 2023.

SEC source: 0000899243-23-010815 · doc4.xml · nonDerivative · entry 1

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,303

F1 · kind: These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023.

F2 · balance_after: Includes 480 shares acquired by the Reporting Person under the Beam Therapeutics Inc. Amended and Restated 2019 Employee Stock Purchase Plan on March 31, 2023.

SEC source: 0000899243-23-010140 · doc4.xml · nonDerivative · entry 3

Bellon Christine · CIK 0001963878 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,882

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal annual installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.

SEC source: 0000899243-23-010138 · doc4.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 115,962

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal annual installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with the BEAM through each vesting date.

SEC source: 0000899243-23-010137 · doc4.xml · derivative · entry 6

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 196,904

Underlying: Common Stock · 13,850 shares

Expires 2029-05-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: This stock option vests as to 25% on the first anniversary of the vesting commencement date, October 1, 2019, and at a rate of 2.78% each month thereafter until the option is fully vested. ..

SEC source: 0000899243-23-010137 · doc4.xml · nonDerivative · entry 3

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,129,153

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-23-010137 · doc4.xml · nonDerivative · entry 2

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,115,303

F3 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under BEAM's 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the BEAM's common stock. The RSUs vest in four substantially equal annual installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.

SEC source: 0000899243-23-010134 · doc4.xml · nonDerivative · entry 1

Simon Amy · CIK 0001963879 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,129

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal annual installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.

SEC source: 0000899243-23-010132 · doc4.xml · nonDerivative · entry 1

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,277

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal annual installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.

SEC source: 0000899243-23-010140 · doc4.xml · derivative · entry 5

Bellon Christine · CIK 0001963878 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,736

Underlying: Common Stock · 2,669 shares

Expires 2029-05-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This stock option vests as to 25% on the first anniversary of the vesting commencement date, May 17, 2020, and at a rate of 2.78% each month thereafter until the option is fully vested.

SEC source: 0000899243-23-010140 · doc4.xml · derivative · entry 4

Bellon Christine · CIK 0001963878 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,674

Underlying: Common Stock · 6,272 shares

Expires 2029-05-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This stock option vests as to 25% on the first anniversary of the vesting commencement date, May 16, 2020, and at a rate of 2.78% each month thereafter until the option is fully vested.

SEC source: 0000899243-23-010140 · doc4.xml · nonDerivative · entry 2

Bellon Christine · CIK 0001963878 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,382

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-23-010140 · doc4.xml · nonDerivative · entry 1

Bellon Christine · CIK 0001963878 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,713

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-23-010137 · doc4.xml · nonDerivative · entry 1

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,059,053

F1 · kind: Distribution of Beam Therapeutics Inc. ("BEAM") common stock held by ARCH Venture Fund IX, L.P. to its partners for no consideration.

F2 · balance_after: Includes 308 shares and acquired by the Reporting Person under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2022.

SEC source: 0000899243-23-010138 · doc4.xml · derivative · entry 2

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2033-01-31

F2 · derivative.exercise_date: This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with BEAM through each vesting date.

SEC source: 0000899243-23-010137 · doc4.xml · derivative · entry 5

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 112,500

Underlying: Common Stock · 112,500 shares

Expires 2033-01-31

F4 · derivative.exercise_date: This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the reporting person's continued service with BEAM through each vesting date.

SEC source: 0000899243-23-010132 · doc4.xml · derivative · entry 2

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2033-01-31

F2 · derivative.exercise_date: This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with BEAM through each vesting date.

SEC source: 0000950170-23-013483 · ownership.xml · derivative · entry 1

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2033-01-31

F1 · security: On March 31, 2023, the Reporting Person filed a Form 4 that reported the acquisition of a stock option. The Form 4 inadvertently reported the number of stock options acquired (and the number of shares of common stock underlying such stock options) as 20,000 when, as reported in this amendment, the correct number is 40,000.

F2 · derivative.exercise_date: This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with Beam Therapeutics Inc. through each vesting date.

SEC source: 0000899243-23-002957 · doc4.xml · derivative · entry 6

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 185,565

Underlying: Common Stock · 36,152 shares

Expires 2029-08-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F5 · derivative.exercise_date: The option vested as to 25% on the first anniversary of the of the vesting commencement date, August 20, 2019, and continues to vest at a rate of 2.78% each month thereafter until the option is fully vested.

SEC source: 0000899243-23-002957 · doc4.xml · nonDerivative · entry 4

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,277

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.24, inclusive. The Reporting Person undertakes to provide BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000899243-23-002957 · doc4.xml · nonDerivative · entry 3

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,429

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0000899243-23-002957 · doc4.xml · derivative · entry 5

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 221,717

Underlying: Common Stock · 1,102 shares

Expires 2029-08-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F5 · derivative.exercise_date: The option vested as to 25% on the first anniversary of the of the vesting commencement date, August 20, 2019, and continues to vest at a rate of 2.78% each month thereafter until the option is fully vested.

SEC source: 0000899243-23-002957 · doc4.xml · nonDerivative · entry 2

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,277

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.48, inclusive. The Reporting Person undertakes to provide Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000899243-23-002957 · doc4.xml · nonDerivative · entry 1

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,379

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0000899243-23-002666 · doc4.xml · derivative · entry 6

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 222,819

Underlying: Common Stock · 14,810 shares

Expires 2029-08-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F5 · derivative.exercise_date: The option vested as to 25% on the first anniversary of the of the vesting commencement date, August 20, 2019, and continues to vest at a rate of 2.78% each month thereafter until the option is fully vested.

SEC source: 0000899243-23-002666 · doc4.xml · nonDerivative · entry 4

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,277

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.10, inclusive. The Reporting Person undertakes to provide BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000899243-23-002666 · doc4.xml · nonDerivative · entry 3

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,087

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0000899243-23-002666 · doc4.xml · derivative · entry 5

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 237,629

Underlying: Common Stock · 5,426 shares

Expires 2029-08-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F5 · derivative.exercise_date: The option vested as to 25% on the first anniversary of the of the vesting commencement date, August 20, 2019, and continues to vest at a rate of 2.78% each month thereafter until the option is fully vested.

SEC source: 0000899243-23-002666 · doc4.xml · nonDerivative · entry 2

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,277

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.18, inclusive. The Reporting Person undertakes to provide Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000899243-23-002666 · doc4.xml · nonDerivative · entry 1

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,703

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0000899243-23-002260 · doc4.xml · derivative · entry 3

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 243,055

Underlying: Common Stock · 39,886 shares

Expires 2029-08-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.

F5 · derivative.exercise_date: The option vested as to 25% on the first anniversary of the of the vesting commencement date, August 20, 2019, and continues to vest at a rate of 2.78% each month thereafter until the option is fully vested.

SEC source: 0000899243-23-002260 · doc4.xml · nonDerivative · entry 2

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,277

F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.50, inclusive. The Reporting Person undertakes to provide BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · balance_after: Includes 308 shares acquired by the Reporting Person under the Beam Therapeutics Inc. ("BEAM") Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2022.

SEC source: 0000899243-23-002260 · doc4.xml · nonDerivative · entry 1

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,472

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.

F2 · balance_after: Includes 308 shares acquired by the Reporting Person under the Beam Therapeutics Inc. ("BEAM") Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2022.

SEC source: 0000899243-23-000973 · doc4.xml · derivative · entry 10

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,905

Underlying: Common Stock · 40,297 shares

Expires 2028-05-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The shares subject to this stock option vested 25% on the first anniversary of the vesting commencement date, February 26, 2018, and the remaining shares vested in 36 substantially equal monthly installments thereafter.

SEC source: 0000899243-23-000973 · doc4.xml · derivative · entry 9

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,326 shares

Expires 2029-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option award vested upon the achievement of a closing price hurdle following BEAM's initial public offering (which closing price hurdle has been achieved) in three equal installments on December 21, 2021, June 30, 2022 and December 31, 2022.

SEC source: 0000899243-23-000973 · doc4.xml · derivative · entry 8

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,106 shares

Expires 2028-05-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option award vested upon the achievement of a closing price hurdle following BEAM's initial public offering (which closing price hurdle has been achieved) in three equal installments on December 21, 2021, June 30, 2022 and December 31, 2022.

SEC source: 0000899243-23-000973 · doc4.xml · nonDerivative · entry 7

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,962

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0000899243-23-000973 · doc4.xml · nonDerivative · entry 6

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,562

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.82 to $39.75, inclusive. The Reporting Person undertakes to provide BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000899243-23-000973 · doc4.xml · nonDerivative · entry 5

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,462

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.66 to $38.48, inclusive. The Reporting Person undertakes to provide BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.